![]() |
市場調查報告書
商品編碼
1500319
全球腦圖譜儀器市場 2024-2031Global Brain Mapping Instruments Market 2024-2031 |
全球腦圖譜儀器市場預計在預測期內(2024-2031)將以 6.1%的年複合成長率成長。全球腦圖譜儀器市場的推動因素包括神經科學研究的進步、神經系統疾病的日益普及、技術創新、政府和私人資金、臨床應用、意識和教育的提高、全球化、夥伴關係和監管環境。神經科學研究的進步、對捕捉詳細資料的複雜工具的需求,以及阿茲海默症、帕金森氏症、癲癇症和中風等神經系統疾病的日益流行,推動了對大腦測繪儀器的需求。政府和私人資助措施以及對大腦健康和早期檢測的認知的提高有助於市場成長。產業參與者、學術機構和研究組織之間的合作促進了腦圖儀器的創新。
市場動態
Global Brain Mapping Instruments Market Size, Share & Trends Analysis Report by Product (Computed Axial Tomography (CAT), Position Emission Tomography, Electroencephalography (EEG), Functional Near-Infrared Spectroscopy (fNIRS), Functional Magnetic Resonance Imaging (fMRI), and Others) and by End Users (Hospitals and Clinics, Diagnostic Centers, and Others) Forecast Period (2024-2031)
The global brain mapping instruments Market is anticipated to grow at a considerable CAGR of 6.1% during the forecast period (2024-2031). The global brain mapping instruments market is fueled by advancements in neuroscience research, the increasing prevalence of neurological disorders, technological innovations, government, and private funding, clinical applications, increasing awareness and education, globalization, partnerships, and regulatory landscape. Advancements in neuroscience research, the need for sophisticated tools to capture detailed data, and the increasing prevalence of neurological disorders like Alzheimer's, Parkinson's, epilepsy, and stroke drive the demand for brain mapping instruments. Government and private funding initiatives, as well as increased awareness about brain health and early detection, contribute to market growth. Collaborations between industry players, academic institutions, and research organizations foster innovation in brain mapping instruments.
Market Dynamics
Increased Diagnosis and Monitoring Needs
Global health is at risk from neurological disorders, which call for precise diagnosis and ongoing observation. Tools for brain mapping are essential for the advancement of disease and the effectiveness of treatment. According to the World Health Organization (WHO), in March 2024, there was a significant global prevalence of neurological conditions, affecting over 3.0 billion individuals. Neurological conditions have emerged as the primary cause of ill health and disability globally. The overall burden of disability, illness, and premature death caused by these conditions has witnessed an 18.0% increase. Notably, access to treatment for neurological conditions varies, with high-income countries having substantially more neurological professionals per 100,000 individuals compared to low- and middle-income countries, where over 80.0% of neurological deaths and health loss occur.
Increased Funding for Brain Mapping Research
Brain Connects offers significant funding for brain mapping research, promoting the development of novel technologies and propelling market expansion via partnerships, technology transfer, and research product commercialization. For instance, National Institute of Neurological Disorders and Stroke (.gov), in September 2023, the NIH BRAIN Initiative launched projects to develop innovative technologies to map the brain in detail. The initiative aims to uncover the logic of the brain's neural code, helping to understand how it makes us who we are and how it could be re-wired to treat brain diseases. The initial round of BRAIN CONNECTS awards supports 11 grants, totaling $150.0 million over five years. The projects will use cutting-edge technology to image and analyze brain connectivity, develop pipelines for data collection and analysis, and develop complementary brain mapping technologies.
Market Segmentation
Computed Axial Tomography (CAT) is Projected to Emerge as the Largest Segment
Based on the disease indication, the global brain mapping instruments market is sub-segmented into computed axial tomography (CAT), positron emission tomography, electroencephalography (EEG), functional near-infrared spectroscopy (fNIRS), functional magnetic resonance imaging (fMRI), and others. Among these, the computed axial tomography (CAT) sub-segment is expected to hold the largest share of the market. The primary factor supporting the segment's growth includes the use of neuroimaging, such as MRIs and CT scans, which is growing in the diagnosis and monitoring of neurological diseases. This rise has been prompted by the need for sophisticated brain mapping tools. According to the Diagnostic Imaging Dataset Statistical, in May 2023, the total number of imaging tests reported in England from February 2022 to January 2023 was 43.4 million. In January 2023, the most commonly performed tests were Plain Radiography (X-ray) with 1.7 million, followed by Diagnostic Ultrasonography (Ultrasound) with 0.8 million, Computerized Axial Tomography (CT Scan) with 0.5 million, and Magnetic Resonance Imaging (MRI) with 0.3 million.
Hospitals and Clinics Sub-segment to Hold a Considerable Market Share
To enhance the clinical need and demand for precision medicine in neurosurgery and improve patient outcomes during tumor removal, a brain mapping gadget is being introduced. This technology allows surgeons to navigate essential brain locations with accuracy. For instance, in August 2022, Delhi Hospital launched a unique "brain mapping device," claiming it is the first of its kind in the country. The device combines research and advanced technology to improve treatment for brain tumors and avoid damage to critical brain areas.
The global brain mapping instruments market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Government for Healthcare Innovation in the Asia-Pacific Region
The government's focus on healthcare infrastructure and increased funding fosters innovation in the sector, including support for brain mapping instrument manufacturers to improve product accuracy, efficiency, and affordability. According to Healthcareradius, in February 2024, the total healthcare expenditure showed an increase from $9.6 billion in 2023-24 to $10.9 billion in 2024-25. Additionally, there has been a significant increase in the allocation for the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PMABHIM), which has risen from $25.4 billion in 2023-24 to $49.7 billion in 2024-25.
North America Holds Major Market Share
The increasing dementia prevalence prompts investments in advanced neuroimaging technologies, focusing on brain mapping instruments with higher sensitivity, resolution, and specificity for early dementia detection and disease progression monitoring. According to the World Health Organization, in March 2023, Dementia affects a significant number of individuals globally, with over 55.0 million individuals currently living with the condition. The majority of these individuals (over 60.0%) reside in low- and middle-income countries. Each year, there are nearly 10.0 million new cases reported. Alzheimer's disease, the most common form of dementia, accounts for 60-70.0% of these cases. Dementia is a leading cause of death and contributes to disability and dependency among older individuals globally. In 2019, the economic cost of dementia was estimated at $1.3 trillion, with approximately 50.0% of these expenses attributed to informal carers, which provide an average of 5 hours of care and supervision per day. Women are disproportionately affected by dementia, both in terms of higher disability-adjusted life years and mortality rates, in addition to being responsible for 70.0% of the caregiving hours for individuals with dementia.
The major companies serving the global brain mapping instruments market include General Electric Co., Koninklijke Philips N.V., Medtronic PLC, Canon Medical Systems Corp., and Siemens Healthineers Co., among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers, and acquisitions to stay competitive in the market. For instance, in May 2023, Lenox Hill Hospital adopted Quicktome, a brain-mapping neurotechnology, to improve neurosurgery efficiency. The FDA-cleared platform uses MRI scans to automatically map a patient's unique brain network before surgery.